Leaders of the Global Liquid Biopsy Revolution

As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).

SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Biotechnology

Life Sciences

Pharmaceutical

Sysmex Inostics

Sysmex Inostics' headquarters in Baltimore, MD, United States

Description

People (7)

Yosuke Baba

Jen Swindell (Preston)

Kellie Quash

Cathryn Mullen

Brittany Lanzetta

Papa Kofi F. Baffour-Awuah

Chris Dougherty

Jobs